heart failure prevention

Precision Prescribing of SGLT2 Inhibitors in Type 2 Diabetes for Primary Prevention of Heart Failure

By MedXY 06/10/2026

A validation study developed SABRE, a model that estimates how much SGLT2 inhibitors can reduce heart failure risk in people with type 2 diabetes, helping clinicians target preventive treatment more precisely.

Cardiology Diabetes & Endocrinology news

Precision Prescribing of SGLT2 Inhibitors in People With Type 2 Diabetes for Primary Prevention of Heart Failure: Model Development and Validation Study

By MedXY 06/10/2026

The SABRE model estimates which people with type 2 diabetes may benefit most from SGLT2 inhibitors to prevent heart failure before it develops.

Cardiology Diabetes & Endocrinology news

Precision Prescribing of SGLT2 Inhibitors in Type 2 Diabetes for Primary Prevention of Heart Failure

By MedXY 06/03/2026

A validated model, SABRE, estimates who with type 2 diabetes may gain the most heart-failure prevention benefit from SGLT2 inhibitors, enabling more precise, individualized prescribing.